Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

U.S. medical device maker Becton Dickinson is considering a potential separation of its life sciences unit at a valuation of about $30 billion, a person familiar with the matter said on Monday. The ...

Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The ...

Headquartered in Franklin Lakes, New Jersey, Becton, Dickinson and Company (BDX) is a global leader in medical technology ...

Shares of Becton Dickinson & Co. BDX slipped 1.60% to $225.85 Wednesday, on what proved to be an all-around rough trading ...

StockNews.com upgraded shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) from a hold rating to a buy rating in a research note released on Wednesday morning. Separately ...

Becton, Dickinson and Company (BDX, Financials) announced a major strategic shift with plans to separate its Biosciences and Diagnostic Solutions unit, aiming to create two independent ...

Becton Dickinson & Co. closed 2.75% below its 52-week high of $251.99, which the company reached on February 3rd.

Citi analyst Joanne Wuensch maintained a Buy rating on Becton Dickinson (BDX – Research Report) today. The company’s shares closed last Friday ...

Headquartered in Franklin Lakes, New Jersey, Becton, Dickinson and Company (BDX) is a global leader in medical technology dedicated to advancing healthcare. With a market cap of $64.5 billion ...

Shares of Becton Dickinson & Co. BDX slid 7.28% to $227.21 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.36% to 6,083 ...